Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Neumora logo — Pioneering a new era of medicines for brain diseases

Neumora

Pioneering a new era of medicines for brain diseases

Founded 2020 United States Watertown, United States 111 employees Series B Total: $612.00M Biotechnology, Health Care

General Information

Company Name Neumora
Founded Year 2020
Location United States Watertown, United States +1
Founders / Decision Makers
Team member Team member
Employees 111
Industries Biotechnology, Health Care
Funding Stage Series B
Social

Get notified when Neumora moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

AI Insight

Bounce Watch AI
2 months ago

Neumora is strategically bolstering its public profile and community engagement through partnerships with key advocacy organizations like the Alzheimer's Association and active participation in mental health awareness events. These recent initiatives highlight a deliberate focus on patient advocacy and brand building within the brain disease sector. This suggests the company is cultivating a supportive ecosystem for its future therapies, complementing its pipeline development.

Signal Types
Partnership Community Engagement
Strategic Labels
Patient Advocacy Brand Building Market Awareness
Next Move: Clinical Trials
·
Impact: 7/10
·
Ideal For: Biotech VCs — Neuroscience & Patient Advocacy

About Neumora

Neumora, founded in 2020 in the United States, is a pioneering company in the Biotechnology and Health Care industries, with a mission to redefine treatment methodologies for brain diseases. Operating under the slogan, "Pioneering a new era of medicines for brain diseases," Neumora addresses a critical unmet medical need affecting over 1.5 billion global patients.

The company adopts a unique precision neuroscience approach to develop novel therapies focusing on both neuropsychiatric and neurodegenerative disorders. Their pipeline currently includes seven programs at various stages, targeting new mechanisms to substantially improve patient outcomes and quality of life.

Neumora's strategic roadmap recently received significant validation with a $112.00M Series B investment on 11 October 2022, backed by renowned investors such as Arch Venture Partners, F-Prime Capital, Polaris Partners, Invus, and others, underscoring investor confidence in its innovative approach and transformative potential.

Taxonomy: brain diseases, neuroscience, neuropsychiatric disorders, neurodegenerative diseases, precision neuroscience, novel mechanisms of action, clinical-stage biotechnology, psychiatric treatments, neuroscience drug development, data science integration, novel therapies, pipeline development, therapeutic innovation, brain health, clinical programs

Services & Products

Development of precision medicines for brain diseases
Drug pipeline targeting novel mechanisms of action
Integration of translational, clinical, and computational tools

Target Customers

Patients with brain diseases Medical professionals in neurology and psychiatry Healthcare providers focused on CNS disorders

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 10
Investor Investor Investor Investor Investor Investor
•••• •••• 		11 Oct 2022
Series A •••••• - 07 Oct 2021
Corporate Round •••••• - 07 Oct 2021
Venture Round •••••• - 01 Oct 2018

Neumora Alternatives & Competitors

View All Alternatives
Neumora vs
Psy Therapeutics
Psy Therapeutics United States

Creating new futures in central nervous system (CNS) treatment and care.

Seed
11 employees
Biotechnology, Health Care
Compare Neumora vs Psy Therapeutics
Neumora vs
Gate Neurosciences
Gate Neurosciences United States

Brain Health, Reimagined

Series Unknown
15 employees
Biotechnology, Health Care
Compare Neumora vs Gate Neurosciences
Neumora vs
CuraSen Therapeutics, Inc.
CuraSen Therapeutics, Inc. United States

Targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN

Grant
20 employees
Biotechnology, Health and Wellness
Compare Neumora vs CuraSen Therapeutics, Inc.
Also compare with: Neumora vs Vigil Neuroscience Vigil Neuroscience View all alternatives

FAQ About Neumora

Pioneering a new era of medicines for brain diseases
Neumora was founded in 2020.
Neumora is headquartered in Watertown, United States.
Neumora operates in the following industries: Biotechnology, Health Care.
Neumora has approximately 111 employees.
Neumora has completed 4 funding rounds, raising a total of $612.00M. The latest funding stage is Series B.
Neumora offers: Development of precision medicines for brain diseases, Drug pipeline targeting novel mechanisms of action, Integration of translational, clinical, and computational tools.
Top alternatives and competitors to Neumora include Psy Therapeutics, Gate Neurosciences, CuraSen Therapeutics, Inc., Amsterdam UMC - Amsterdam Neuroscience, Alector. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Neumora and Psy Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Neumora and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy